
    
      An anticipated 30 participants with newly diagnosed active ulcerative colitis will be
      recruited to participate in a randomized control trial, with 50% of the subjects distributed
      to the supplement (n=15) and the other 50% provided a placebo control (n=15). This is
      considered as a "proof of concept" study to determine if there is evidence that a
      multi-ingredient supplement (immunonutrition) will reduce UC disease severity.
    
  